TrialJAMA oncology2019

Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer.

Bram De Laere et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.